Stock Financial Ratios, Dividends, Split History

MGEN / Miragen Therapeutics financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price7.35
Volume126,200.00
Market Cap ($M)218.59
Enterprise Value ($M)174.07
Book Value ($M)72.71
Book Value / Share2.41
Price / Book5.49
NCAV ($M)72.07
NCAV / Share2.39
Price / NCAV3.08
Share Statistics
Common Stock Shares Outstanding 22,568,006
Common Shares Outstanding 30,172,086
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.55
Return on Assets (ROA)-6.22
Return on Equity (ROE)81.33
Balance Sheet (mrq) ($M)
Assets86.99
Liabilities14.29
Quick Ration/a
Current Ratio20.87
Income Statement (mra) ($M)
License And Services Revenue3,097,000.00
Revenue From Grants906,000.00
Sales Revenue Net4,003,000.00
Operating Income-26.53
Net Income-26.51
Earnings Per Share Basic And Diluted-1.38
Cash Flow Statement (mra) ($M)
Cash From Operations-28.17
Cash from Investing1.03
Cash from Financing1.03
Identifiers and Descriptors
CUSIP60463E103
Central Index Key (CIK)1590750
Related CUSIPS
826640203 826640104

Split History

Stock splits are used by Miragen Therapeutics to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Related News Stories

miRagen Therapeutics' (MGEN) CEO William Marshall on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Good afternoon everyone, and welcome to the miRagen Therapeutics First Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. And as a reminder, today's call is being recorded. (43-0)

BRIEF-Miragen Therapeutics Announces New Data Showing Administration Of MRG-110 Improved Tissue Perfusion And Wound Healing

2018-04-27 reuters
* MIRAGEN THERAPEUTICS ANNOUNCES NEW DATA SHOWING ADMINISTRATION OF MRG-110 IMPROVED TISSUE PERFUSION AND WOUND HEALING IN LATE STAGE PRECLINICAL STUDIES (43-0)

Your Daily Pharma Scoop: Esperion Gains On Data, AnaptysBio's ANB020, Tesaro Reports Promising Data

2018-03-28 seekingalpha
Esperion Therapeutics (NASDAQ:ESPR) shares have moved up sharply after the company announced top-line results from a phase 2 study (1002-039) evaluating the LDL-C lowering efficacy and safety of bempedoic acid 180 mg added-on to stable background therapy of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in 58 patients with hypercholesterolemia. (158-3)

miRagen Therapeutics' (MGEN) CEO William Marshall on Q4 2017 Results - Earnings Call Transcript

2018-03-15 seekingalpha
Good afternoon, and welcome to the miRagen Therapeutics Fourth Quarter and Full Year 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this conference call is being recorded. (43-0)

BRIEF-Miragen Therapeutics Reports Qtrly ‍loss Per Share $0.29​

2018-03-14 reuters
* MIRAGEN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE (43-0)

CUSIP: 60463E103